Karuna Therapeutics, Inc. announced the appointment of Charmaine Lykins as chief commercial officer, effective November 29, 2021. Ms. Lykins brings over 25 years of psychiatry and neuroscience-focused pharmaceutical launch experience across multiple organizations recognized as leaders in developing and commercializing medicines for central nervous system disorders, including Eli Lilly, Lundbeck, Sunovion and ACADIA Pharmaceuticals.